Spectrum Pharmaceutical’s Access4Me

Spectrum Pharmaceuticals offers the Access4Me program to provide access and reimbursement support to patients who have been prescribed Rolvedon (Table).

Access4Me

Access4Me offers a comprehensive list of programs such as the Rolvedon Copay Assistance Program, the Rolvedon Patient Assistance Program, and the First-Cycle Patient Support Program.

Rolvedon Copay Assistance Program

The Rolvedon Copay Assistance Program may reduce out-of-pocket costs for patients with commercial insurance to as little as $0, up to a maximum annual benefit of $15,000 per 12-month enrollment period. Patients may be eligible if they:

• Have commercial or private insurance that covers Rolvedon
• Have a copay for Rolvedon
• Are not participating in Medicare, Medicaid, Medigap, Veterans Affairs, Department of Defense, TRICARE, or other similar federal or state programs
• Are a resident of the United States.

Rolvedon Patient Assistance Program

Patients who are uninsured or underinsured may be eligible to receive Rolvedon at no cost through the Patient Assistance Program. Patients may be eligible if they:

• Are uninsured or underinsured for Rolvedon
• Are a resident of the United States
• Demonstrate financial need
• Have an annual income of <500% of the federal poverty level adjusted for family size.

First-Cycle Patient Support Program

New patients can receive their first-cycle dose of Rolvedon free of charge. When enrolling the patient, simply check First-Cycle Patient Support on the enrollment form. Access4Me will conduct the benefits investigation, communicate the results to your office, and confirm patient eligibility for the free dose. This program is limited to one free dose per patient. Patients may be eligible if they:

• Are a new patient, enrolled in Access4Me
• Are a resident of the United States.

To enroll your patient in the Access4Me program, visit the Access4Me website.

TABLE Spectrum Oncology Supportive Drug